Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients.

Frerichs KA, Bosman PWC, van Velzen JF, Fraaij PLA, Koopmans MPG, Rimmelzwaan GF, Nijhof IS, Bloem AC, Mutis T, Zweegman S, van de Donk NWCJ.

Haematologica. 2019 Sep 26. pii: haematol.2019.231860. doi: 10.3324/haematol.2019.231860. [Epub ahead of print]

2.

A dominant activating RAC2 variant associated with immunodeficiency and pulmonary disease.

Smits BM, Lelieveld PHC, Ververs FA, Turkenburg M, de Koning C, van Dijk M, Leavis HL, Boelens JJ, Lindemans CA, Bloem AC, van de Corput L, van Montfrans J, Nierkens S, van Gijn ME, Geerke DP, Waterham HR, Koenderman L, Boes M.

Clin Immunol. 2019 Aug 2:108248. doi: 10.1016/j.clim.2019.108248. [Epub ahead of print] No abstract available.

PMID:
31382036
3.

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients.

Franssen LE, Nijhof IS, Bjorklund CC, Chiu H, Doorn R, van Velzen J, Emmelot M, van Kessel B, Levin MD, Bos GMJ, Broijl A, Klein SK, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Raymakers R, Sonneveld P, Zweegman S, Lokhorst HM, Thakurta A, Qian X, Mutis T, van de Donk NWCJ.

Oncotarget. 2018 Sep 21;9(74):34009-34021. doi: 10.18632/oncotarget.26131. eCollection 2018 Sep 21.

4.

All-printed cell counting chambers with on-chip sample preparation for point-of-care CD4 counting.

Wasserberg D, Zhang X, Breukers C, Connell BJ, Baeten E, van den Blink D, S O L À Benet È, Bloem AC, Nijhuis M, Wensing AMJ, Terstappen LWMM, Beck M.

Biosens Bioelectron. 2018 Oct 15;117:659-668. doi: 10.1016/j.bios.2018.07.002. Epub 2018 Jul 3.

5.

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients.

Franssen LE, Nijhof IS, Couto S, Levin MD, Bos GMJ, Broijl A, Klein SK, Ren Y, Wang M, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Raymakers R, Leguit RJ, Sonneveld P, Zweegman S, Lokhorst H, Mutis T, Thakurta A, Qian X, van de Donk NWCJ.

Haematologica. 2018 Aug;103(8):e368-e371. doi: 10.3324/haematol.2017.186601. Epub 2018 Mar 15. No abstract available.

6.

Lethal neonatal bone marrow failure syndrome with multiple congenital abnormalities, including limb defects, due to a constitutional deletion of 3' MECOM.

van der Veken LT, Maiburg MC, Groenendaal F, van Gijn ME, Bloem AC, Erpelinck C, Gröschel S, Sanders MA, Delwel R, Bierings MB, Buijs A.

Haematologica. 2018 Apr;103(4):e173-e176. doi: 10.3324/haematol.2017.185033. Epub 2018 Feb 8. No abstract available.

7.

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.

Krejcik J, Frerichs KA, Nijhof IS, van Kessel B, van Velzen JF, Bloem AC, Broekmans MEC, Zweegman S, van Meerloo J, Musters RJP, Poddighe PJ, Groen RWJ, Chiu C, Plesner T, Lokhorst HM, Sasser AK, Mutis T, van de Donk NWCJ.

Clin Cancer Res. 2017 Dec 15;23(24):7498-7511. doi: 10.1158/1078-0432.CCR-17-2027. Epub 2017 Oct 12.

8.

Novel data analysis method for multicolour flow cytometry links variability of multiple markers on single cells to a clinical phenotype.

Tinnevelt GH, Kokla M, Hilvering B, van Staveren S, Folcarelli R, Xue L, Bloem AC, Koenderman L, Buydens LMC, Jansen JJ.

Sci Rep. 2017 Jul 14;7(1):5471. doi: 10.1038/s41598-017-05714-1.

9.

Lymphoblastic lymphoma with a triple-hit profile: a rare but distinct and relevant entity.

Hiemcke-Jiwa LS, Leguit RJ, van der Veken LT, Buijs A, Leeuwis JW, de Boer M, Jiwa NM, Bloem AC, Petersen EJ, de Weger RA, Huibers MMH.

Hum Pathol. 2017 May;63:171-176. doi: 10.1016/j.humpath.2016.11.002. Epub 2016 Nov 17.

PMID:
27867103
10.

Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches.

Antonelli A, Noort WA, Jaques J, de Boer B, de Jong-Korlaar R, Brouwers-Vos AZ, Lubbers-Aalders L, van Velzen JF, Bloem AC, Yuan H, de Bruijn JD, Ossenkoppele GJ, Martens AC, Vellenga E, Groen RW, Schuringa JJ.

Blood. 2016 Dec 22;128(25):2949-2959. doi: 10.1182/blood-2016-05-719021. Epub 2016 Oct 12.

PMID:
27733356
11.

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.

Nijhof IS, Franssen LE, Levin MD, Bos GMJ, Broijl A, Klein SK, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Ypma PF, Raymakers R, van Spronsen DJ, Westerweel PE, Oostvogels R, van Velzen J, van Kessel B, Mutis T, Sonneveld P, Zweegman S, Lokhorst HM, van de Donk NWCJ.

Blood. 2016 Nov 10;128(19):2297-2306. doi: 10.1182/blood-2016-07-729236. Epub 2016 Sep 19.

PMID:
27647864
12.

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.

Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, Groen RW, van Duin M, Sonneveld P, Minnema MC, Zweegman S, Chiu C, Bloem AC, Mutis T, Lokhorst HM, Sasser AK, van de Donk NW.

Blood. 2016 Aug 18;128(7):959-70. doi: 10.1182/blood-2016-03-703439. Epub 2016 Jun 15.

PMID:
27307294
13.

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.

Nijhof IS, Groen RW, Lokhorst HM, van Kessel B, Bloem AC, van Velzen J, de Jong-Korlaar R, Yuan H, Noort WA, Klein SK, Martens AC, Doshi P, Sasser K, Mutis T, van de Donk NW.

Leukemia. 2015 Oct;29(10):2039-49. doi: 10.1038/leu.2015.123. Epub 2015 May 15.

PMID:
25975191
14.

Association of IgM monoclonal gammopathy with progressive muscular atrophy and multifocal motor neuropathy: a case-control study.

Vlam L, Piepers S, Sutedja NA, Jacobs BC, Tio-Gillen AP, Stam M, Franssen H, Veldink JH, Cats EA, Notermans NC, Bloem AC, Wadman RI, van der Pol WL, van den Berg LH.

J Neurol. 2015 Mar;262(3):666-73. doi: 10.1007/s00415-014-7612-4. Epub 2015 Jan 1.

PMID:
25549972
15.

CT screening for pulmonary pathology in common variable immunodeficiency disorders and the correlation with clinical and immunological parameters.

Maarschalk-Ellerbroek LJ, de Jong PA, van Montfrans JM, Lammers JW, Bloem AC, Hoepelman AI, Ellerbroek PM.

J Clin Immunol. 2014 Aug;34(6):642-54. doi: 10.1007/s10875-014-0068-6. Epub 2014 Jun 21.

PMID:
24952009
16.

Inability of monoclonal anti-light chain antibody to detect clonal B-cells in a patient with follicular lymphoma by multicolor flow cytometry.

van Velzen JF, van den Blink D, Wiegers IE, Bloem AC.

J Clin Lab Anal. 2014 Nov;28(6):493-5. doi: 10.1002/jcla.21716. Epub 2014 Mar 22.

17.

Detection of choroid- and retina-antigen reactive CD8(+) and CD4(+) T lymphocytes in the vitreous fluid of patients with birdshot chorioretinopathy.

Kuiper JJ, Rothova A, Schellekens PA, Ossewaarde-van Norel A, Bloem AC, Mutis T.

Hum Immunol. 2014 Jun;75(6):570-7. doi: 10.1016/j.humimm.2014.02.012. Epub 2014 Feb 12.

PMID:
24530754
18.

Measurement of pneumococcal polysaccharide vaccine responses for immunodeficiency diagnostics: combined IgG responses compared to serotype specific IgG responses.

Janssen WJ, Bloem AC, Vellekoop P, Driessen GJ, Boes M, van Montfrans JM.

J Clin Immunol. 2014 Jan;34(1):3-6. doi: 10.1007/s10875-013-9925-y. Epub 2013 Jul 24. No abstract available.

PMID:
23881353
19.

Salivary immune responses to the 7-valent pneumococcal conjugate vaccine in the first 2 years of life.

Rodenburg GD, Sanders EA, van Gils EJ, Veenhoven RH, Zborowski T, van den Dobbelsteen GP, Bloem AC, Berbers GA, Bogaert D.

PLoS One. 2012;7(10):e46916. doi: 10.1371/journal.pone.0046916. Epub 2012 Oct 16.

20.

Inability of a monoclonal anti-light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry.

van Velzen JF, van den Blink D, Bloem AC.

Cytometry B Clin Cytom. 2013 Jan-Feb;84(1):30-2. doi: 10.1002/cyto.b.21044. Epub 2012 Sep 27.

21.

Changes in lymphocyte subsets in workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).

Saberi Hosnijeh F, Lenters V, Boers D, Portengen L, Baeten E, Bueno-de-Mesquita HB, Heederik DJ, Bloem AC, Vermeulen R.

Occup Environ Med. 2012 Nov;69(11):781-6. doi: 10.1136/oemed-2011-100463. Epub 2012 Jul 27.

PMID:
22843439
22.

Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma.

Groen RW, Noort WA, Raymakers RA, Prins HJ, Aalders L, Hofhuis FM, Moerer P, van Velzen JF, Bloem AC, van Kessel B, Rozemuller H, van Binsbergen E, Buijs A, Yuan H, de Bruijn JD, de Weers M, Parren PW, Schuringa JJ, Lokhorst HM, Mutis T, Martens AC.

Blood. 2012 Jul 19;120(3):e9-e16. doi: 10.1182/blood-2012-03-414920. Epub 2012 May 31.

PMID:
22653974
23.

CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia.

van Montfrans JM, Hoepelman AI, Otto S, van Gijn M, van de Corput L, de Weger RA, Monaco-Shawver L, Banerjee PP, Sanders EA, Jol-van der Zijde CM, Betts MR, Orange JS, Bloem AC, Tesselaar K.

J Allergy Clin Immunol. 2012 Mar;129(3):787-793.e6. doi: 10.1016/j.jaci.2011.11.013. Epub 2011 Dec 24.

24.

Defective calcium signaling and disrupted CD20-B-cell receptor dissociation in patients with common variable immunodeficiency disorders.

van de Ven AA, Compeer EB, Bloem AC, van de Corput L, van Gijn M, van Montfrans JM, Boes M.

J Allergy Clin Immunol. 2012 Mar;129(3):755-761.e7. doi: 10.1016/j.jaci.2011.10.020. Epub 2011 Nov 30.

PMID:
22130422
25.

Impact of treatment reduction for childhood acute lymphoblastic leukemia on serum immunoglobulins and antibodies against vaccine-preventable diseases.

van Tilburg CM, Bierings MB, Berbers GA, Wolfs TF, Pieters R, Bloem AC, Sanders EA.

Pediatr Blood Cancer. 2012 May;58(5):701-7. doi: 10.1002/pbc.23258. Epub 2011 Jul 25.

PMID:
21793184
26.

Immune reconstitution in children following chemotherapy for haematological malignancies: a long-term follow-up.

van Tilburg CM, van Gent R, Bierings MB, Otto SA, Sanders EA, Nibbelke EE, Gaiser JF, Janssens-Korpela PL, Wolfs TF, Bloem AC, Borghans JA, Tesselaar K.

Br J Haematol. 2011 Jan;152(2):201-10. doi: 10.1111/j.1365-2141.2010.08478.x. Epub 2010 Nov 28.

PMID:
21114483
27.

Eradication of medullary multiple myeloma by CD4+ cytotoxic human T lymphocytes directed at a single minor histocompatibility antigen.

Spaapen RM, Groen RW, van den Oudenalder K, Guichelaar T, van Elk M, Aarts-Riemens T, Bloem AC, Storm G, Martens AC, Lokhorst HM, Mutis T.

Clin Cancer Res. 2010 Nov 15;16(22):5481-8. doi: 10.1158/1078-0432.CCR-10-1340. Epub 2010 Nov 9.

28.

Reduced versus intensive chemotherapy for childhood acute lymphoblastic leukemia: impact on lymphocyte compartment composition.

van Tilburg CM, van der Velden VH, Sanders EA, Wolfs TF, Gaiser JF, de Haas V, Pieters R, Bloem AC, Bierings MB.

Leuk Res. 2011 Apr;35(4):484-91. doi: 10.1016/j.leukres.2010.10.005. Epub 2010 Nov 3.

PMID:
21051085
29.

Lymphocyte characteristics in children with common variable immunodeficiency.

van de Ven AA, van de Corput L, van Tilburg CM, Tesselaar K, van Gent R, Sanders EA, Boes M, Bloem AC, van Montfrans JM.

Clin Immunol. 2010 Apr;135(1):63-71. doi: 10.1016/j.clim.2009.11.010. Epub 2009 Dec 16.

PMID:
20006554
30.

Rapid identification of clinical relevant minor histocompatibility antigens via genome-wide zygosity-genotype correlation analysis.

Spaapen RM, de Kort RA, van den Oudenalder K, van Elk M, Bloem AC, Lokhorst HM, Mutis T.

Clin Cancer Res. 2009 Dec 1;15(23):7137-43. doi: 10.1158/1078-0432.CCR-09-1914. Epub 2009 Nov 24.

31.

Refined characterization and reference values of the pediatric T- and B-cell compartments.

van Gent R, van Tilburg CM, Nibbelke EE, Otto SA, Gaiser JF, Janssens-Korpela PL, Sanders EA, Borghans JA, Wulffraat NM, Bierings MB, Bloem AC, Tesselaar K.

Clin Immunol. 2009 Oct;133(1):95-107. doi: 10.1016/j.clim.2009.05.020. Epub 2009 Jul 7. Erratum in: Clin Immunol. 2010 Aug;136(2):307-8.

PMID:
19586803
32.

Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis.

Spaapen RM, Lokhorst HM, van den Oudenalder K, Otterud BE, Dolstra H, Leppert MF, Minnema MC, Bloem AC, Mutis T.

J Exp Med. 2008 Nov 24;205(12):2863-72. doi: 10.1084/jem.20080713. Epub 2008 Nov 10.

33.

Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.

van der Spek E, Bloem AC, Lokhorst HM, van Kessel B, Bogers-Boer L, van de Donk NW.

Leuk Res. 2009 Jan;33(1):100-8. doi: 10.1016/j.leukres.2008.06.001. Epub 2008 Jul 14.

PMID:
18621417
34.

A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect.

Rozemuller H, van der Spek E, Bogers-Boer LH, Zwart MC, Verweij V, Emmelot M, Groen RW, Spaapen R, Bloem AC, Lokhorst HM, Mutis T, Martens AC.

Haematologica. 2008 Jul;93(7):1049-57. doi: 10.3324/haematol.12349. Epub 2008 May 19.

35.

High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma.

van der Spek E, Bloem AC, Sinnige HA, Lokhorst HM.

Haematologica. 2007 Dec;92(12):e130-1.

36.

Immunoglobulin gene analysis in polyneuropathy associated with IgM monoclonal gammopathy.

Eurelings M, Notermans NC, Lokhorst HM, van Kessel B, Jacobs BC, Wokke JH, Sahota SS, Bloem AC.

J Neuroimmunol. 2006 Jun;175(1-2):152-9. Epub 2006 Mar 6.

PMID:
16600385
37.

Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma.

van der Spek E, Bloem AC, van de Donk NW, Bogers LH, van der Griend R, Kramer MH, de Weerdt O, Wittebol S, Lokhorst HM.

Haematologica. 2006 Apr;91(4):542-5.

38.

New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathway.

van de Donk NW, Bloem AC, van der Spek E, Lokhorst HM.

Curr Pharm Des. 2006;12(3):327-40. Review.

PMID:
16454747
39.

Growth factors and antiapoptotic signaling pathways in multiple myeloma.

van de Donk NW, Lokhorst HM, Bloem AC.

Leukemia. 2005 Dec;19(12):2177-85. Review.

PMID:
16239913
40.

Geranylgeranylated proteins are involved in the regulation of myeloma cell growth.

van de Donk NW, Lokhorst HM, Nijhuis EH, Kamphuis MM, Bloem AC.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):429-39.

41.

A class II-restricted cytotoxic T-cell clone recognizes a human minor histocompatibility antigen with a restricted tissue distribution.

Holloway PA, Kaldenhoven N, Kok-Schoemaker HM, Dijk Mv, Otten HG, Tilanus M, Postma S, Mutis T, Lokhorst HM, Bloem AC.

Br J Haematol. 2005 Jan;128(1):73-81.

PMID:
15606552
42.

Susceptibility of malignant plasma cells to HA-1(H) specific lysis suggests a role for the minor histocompatibility antigen HA-1 in the graft-versus-myeloma effect.

Holloway PA, Kaldenhoven N, van Dijk M, Bloem AC, de Lau W, van der Zee R, Kircher-Eibl B, Mutis T, Lokhorst HM.

Leukemia. 2004 Sep;18(9):1543-5. No abstract available.

PMID:
15322561
43.

G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma.

van de Donk NW, de Weerdt O, Veth G, Eurelings M, van Stralen E, Frankel SR, Hagenbeek A, Bloem AC, Lokhorst HM.

Leukemia. 2004 Jun;18(6):1078-84.

PMID:
15085157
44.

Illegitimate WNT signaling promotes proliferation of multiple myeloma cells.

Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH, Lokhorst HM, Bloem AC, Clevers H, Nusse R, van der Neut R, Spaargaren M, Pals ST.

Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6122-7. Epub 2004 Apr 5.

45.

Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells.

van de Donk NW, Schotte D, Kamphuis MM, van Marion AM, van Kessel B, Bloem AC, Lokhorst HM.

Clin Cancer Res. 2003 Nov 15;9(15):5735-48.

46.

Gene-expression profiling of CD34+ cells from various hematopoietic stem-cell sources reveals functional differences in stem-cell activity.

Ng YY, van Kessel B, Lokhorst HM, Baert MR, van den Burg CM, Bloem AC, Staal FJ.

J Leukoc Biol. 2004 Feb;75(2):314-23. Epub 2003 Nov 21.

PMID:
14634063
47.

Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels.

van de Donk NW, Kamphuis MM, van Kessel B, Lokhorst HM, Bloem AC.

Blood. 2003 Nov 1;102(9):3354-62. Epub 2003 Jul 10.

PMID:
12855556
49.

The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.

Derksen PW, de Gorter DJ, Meijer HP, Bende RJ, van Dijk M, Lokhorst HM, Bloem AC, Spaargaren M, Pals ST.

Leukemia. 2003 Apr;17(4):764-74.

PMID:
12682635
50.

Antigens shared by malignant plasma cells and normal B cells may be involved in graft versus myeloma.

Holloway PA, Kaldenhoven N, Kok-Schoemaker HM, Van Kessel B, Van Blokland WT, Bloem AC, Lokhorst HM.

Clin Exp Immunol. 2003 Feb;131(2):340-6.

Supplemental Content

Loading ...
Support Center